BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Mettu, NB; Twohy, E; Ou, F-S; Halfdanarson, TR; Lenz, HJ; Breakstone, R; Boland, PM; Crysler, O; Wu, C; Grothey, A; Nixon, AB; Bolch, E; Niedzwiecki, D; Fruth, B; Schweitzer, B; Elsing, A; Hurwitz, H; Fakih, MG; Bekaii-Saab, T

Published Date

  • October 1, 2019

Published In

Volume / Issue

  • 30 /

Published By


  • 1

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Conference Name

  • 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Conference Location

  • Barcelona, SPAIN

Conference Start Date

  • September 27, 2019

Conference End Date

  • October 1, 2019